PTSM: Pharmaceutical Technology Sourcing and Management, Sep 5, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PTSM: Pharmaceutical Technology Sourcing and Management, Sep 5, 2012
APIs
Evaluating Market Opportunities in Orphan Drugs
By Patricia Van Arnum
Although serving niche areas, orphan drugs offer good market opportunities for pharmaceutical companies and their suppliers.
Supply Chain
Moving to Risk-Based Inspections
By Patricia Van Arnum
The Generic Drug User Fee Act seeks to improve and enhance regulatory activities, including achieving parity of inspections between foreign and domestic drug-manufacturing sites for both finished dosage forms and APIs of generic drugs.
Drug Delivery
Drug Delivery Insights: Injectable Drugs
By Patricia Van Arnum
A roundup of the latest developments for drug delivery of parenteral drugs.
Outsourcing
Gauging Biopharm Outsourcing
By Eric Langer
Budgets for biopharmaceutical activities are gaining in select functional areas except outsourcing.
CSR and Sustainability Forum
CSR and Sustainability in the News
A roundup of developments in corporate social responsibility (CSR) and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.
Using Microfluidic Chip Technology for Assessing Drug Quality
By Patricia Van Arnum
A look at PharmaCheck, a field-based tool in development that uses microfluidic chip technology for assessing the quality of medicine in the developing world.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
Click here